Overall market trend: Bearish phase – day 46
Fridays market: Money leaving the market – High selling pressure
TC2000 McClellan: 6
Stocks above 40PMA T2108: 47
VIX: 19
52 week highs (US common stocks): 279
Seasonality:
The historical case: The post-midterm window is the cycle’s strongest stretch. From the 31 October close of a midterm year to the following 30 April, the S&P 500 has been positive in all 19 cycles since 1950, averaging nearly 15%.
The base rate is strong. Since 1950 the S&P 500 has averaged a 1.7% gain in November, tied with December for the best month according to the Stock Trader’s Almanac. In midterm years the Almanac ranks November as the second best month for the DJIA and S&P 500. November also starts the “Best Six Months”. Small caps come into favour in November but don’t really take off until the last two weeks of the year.
The odds favour a positive month, and November–April has the best risk/reward of the four-year cycle. But 2026 starts closer to the highs than most midterm years. Expect smaller gains than the averages, and leadership may sit outside mega-cap tech. A tech-led drawdown in November is entirely possible and wouldn’t break the pattern. History says weak patches before or around the vote have usually been bought.
Indices:
$SOXX No trend
$QQQ: No trend
$SPY: No trend
$RSP: Uptrend
$DIA: No trend
$IWM: Downtrend
$BTC: Downtrend
$SQQQ: No trend
$UVIX: Downtrend
$TLT: Downtrend
$USO: Downtrend
$TNX: Uptrend
$GLD: Downtrend
$SLV: Downtrend
$SLX: Downtrend
2%+ sectors Friday:
- None
2%- sectors Friday:
- $SMH -2.99%
- $XLK -2.01%
Main sectors monthly trailing:
- Leading – $XLV $XHB
- Lagging – $XLE $XLK
Sub sectors monthly trailing:
- Leading – $RTH $JETS
- Lagging – $IGV $SMH
Bitcoin: 64k ish
Current market themes:
Theme 1: Big Pharma & GLP-1 Defensive Leadership
Catalyst: Investors are moving money out of AI and into steady earners. Lilly’s Q3 sales hit $24.4 billion, about $1.9 billion above forecasts, and AbbVie, Lilly and Gilead are trading at or near record highs.
Sectors: Big pharma, obesity drugs (GLP-1), large-cap biotech, medtech.
Conviction: High. Strong earnings plus a defensive bid while a rate hike is coming.
| Ticker | Company | Sector/Industry | Last (13 Nov) | 1D % | Market Cap | YTD | Key Catalyst | Analyst Consensus |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | Pharma / GLP-1 | 1443.50 | 1.26 | ~$1.3T (verify) | verify | Raised 2026 guidance; record highs | verify |
| ABBV | AbbVie Inc. | Pharma | 295.03 | 0.20 | verify | >25% | 52-week highs after Q3 | verify |
| JNJ | Johnson & Johnson | Pharma / Medtech | 285.75 | 0.79 | verify | verify | Defensive rotation | verify |
| MRK | Merck & Co., Inc. | Pharma | 147.76 | 0.55 | verify | verify | Q3 beat | verify |
| AMGN | Amgen Inc. | Biotech / Obesity | 465.67 | -0.30 | verify | verify | Obesity pipeline | verify |
| GILD | Gilead Sciences, Inc. | Biotech | 168.08 | 0.08 | verify | verify | Near record highs | verify |
| AZN | AstraZeneca PLC (ADR) | Pharma | 184.45 | 0.04 | verify | verify | Defensive bid | verify |
| NVO | Novo Nordisk A/S (ADR) | Pharma / GLP-1 | 41.63 | 2.41 | verify | verify | GLP-1 laggard catch-up | verify |
| BMY | Bristol-Myers Squibb Company | Pharma | 63.43 | 1.78 | verify | verify | Value rotation | verify |
| PFE | Pfizer Inc. | Pharma | 28.89 | 0.21 | verify | verify | Low-valuation defensive | verify |
| REGN | Regeneron Pharmaceuticals, Inc. | Biotech | 955.47 | 0.45 | verify | verify | Pipeline momentum | verify |
| VRTX | Vertex Pharmaceuticals Incorporated | Biotech | 538.60 | -0.74 | verify | verify | Defensive growth | verify |
| ISRG | Intuitive Surgical, Inc. | Medtech / Robotics | 443.59 | 0.84 | verify | verify | Procedure growth | verify |
| BSX | Boston Scientific Corporation | Medtech | 44.34 | 0.32 | verify | verify | Medtech rotation | verify |
| VKTX | Viking Therapeutics, Inc. | Biotech / Obesity | 29.22 | 5.95 | verify | verify | Oral VK2735 heading to phase III in Q4 2026 | verify |
| ETFs | XLV (188.85), IHE, IBB, XBI |
Theme 2: Energy & the Hormuz Risk Premium
Catalyst: Energy is 2026’s best-performing sector, and it was one of the groups investors moved into on Friday. The risk is the oil price: Brent traded above $112 at the start of November, and the slide came on growing hopes for a US-Iran peace deal. Brent is now near $96 and WTI near $88.
Sectors: Integrated oil majors, oil producers, oilfield services, refiners, LNG.
Conviction: Medium. It’s an inflation hedge and still a geopolitical hedge, but it depends on what oil does next.
| Ticker | Company | Sector/Industry | Last (13 Nov) | 1D % | Market Cap | YTD | Key Catalyst | Analyst Consensus |
|---|---|---|---|---|---|---|---|---|
| XOM | Exxon Mobil Corporation | Integrated Oil | 170.59 | 0.48 | verify | verify | Hormuz headlines; Q3 beat | verify |
| CVX | Chevron Corporation | Integrated Oil | 219.89 | 1.64 | verify | verify | Oil price sensitivity | verify |
| COP | ConocoPhillips | Oil Producer | 142.28 | 1.59 | verify | verify | Crude rebound | verify |
| EOG | EOG Resources, Inc. | Oil Producer | 158.32 | 1.74 | verify | verify | Went into 2026 completely unhedged | verify |
| OXY | Occidental Petroleum Corporation | Oil Producer | 58.75 | 0.60 | verify | verify | Adjusted EPS of $1.91 | verify |
| DVN | Devon Energy Corporation | Oil Producer | 46.58 | 0.76 | verify | verify | Crude beta | verify |
| FANG | Diamondback Energy, Inc. | Oil Producer | 184.93 | 1.50 | verify | verify | Permian producer | verify |
| SLB | SLB N.V. | Oilfield Services | 51.63 | 1.41 | verify | verify | International spending | verify |
| HAL | Halliburton Company | Oilfield Services | 33.50 | 2.26 | verify | verify | Oilfield services recovery | verify |
| BKR | Baker Hughes Company | Oilfield Services / LNG Equipment | 49.44 | 1.19 | verify | verify | LNG and power equipment | verify |
| VLO | Valero Energy Corporation | Refining | 379.83 | 1.30 | verify | verify | Refining margins | verify |
| MPC | Marathon Petroleum Corporation | Refining | 414.65 | 0.44 | verify | verify | Refining margins | verify |
| PSX | Phillips 66 | Refining / Midstream | 265.98 | 1.17 | verify | verify | Refining plus midstream | verify |
| LNG | Cheniere Energy, Inc. | LNG Export | 308.75 | -0.24 | verify | verify | Global LNG demand | verify |
| KGS | Kodiak Gas Services, Inc. | Gas Compression | 45.16 | 1.71 | verify | verify | Jumped on a record quarter | verify |
| ETFs | XLE (64.96), XOP, OIH, VDE |
What type of market are we in: Choppy, Tech remains weak
Key things for this week: This week is all about Nvidia on Tuesday evening, and it’s an unusual setup. It’s the company’s first report since Jensen Huang resigned as CEO on 12 November, with CFO Colette Kress now interim CEO. The stock had already fallen 29.4% in five weeks with no new results, and its P/E is the lowest since 2019. Nvidia guided to revenue of $108.0bn (plus or minus 2%), almost double the same quarter a year earlier. At the 12 November close it was worth about $4.01 trillion, more than the other 83 companies reporting that week combined, so its numbers and guidance will set the tone for the whole AI and semis complex. Around it, the week is a holiday-shopping test: Home Depot and Disney report Tuesday morning, Target, Lowe’s and TJX on Wednesday morning, and Walmart on Thursday morning. Tariff refunds are a common theme across the retailers. On the macro side, October retail sales land on Tuesday morning and the Fed’s October meeting minutes on Wednesday afternoon. UK CPI is also due this week.
Are breakouts working: No
Are breakouts likely to work for the next 3 – 5 days: No
Are breakdowns likely to work for the next 3 – 5 days: No
Should I be trading: Quick 5m ROE’s
Todays watchlist (stocks setting up): Nothing at the moment

